Abstract
The purpose of present research work is to develop osmotic drug delivery of Lansoprazole. Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Lansoprazole has been selected as a model drug to study the effect of in-situ pore former osmotic capsule because it is an effective proton pump inhibitor drug. The proposed work is envisaged to carry out the preformulation, optimization, development of in-situ orifice forming osmotic capsules and then formulation and evaluation of osmotic capsule. In-situ pore forming osmotic capsule of Lansoprazole is the one which suit the concept of better patient compliance, delayed release, more efficacies and enough bioavailability to show required pharmacological action and less gastrointestinal side effects. The Lansoprazole osmotic drug delivery system was successfully developed and evaluated.